Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells  by Chène, Patrick et al.
Study of the cytotoxic e¡ect of a peptidic inhibitor of
the p53^hdm2 interaction in tumor cells
Patrick Che'ne, Jean Fuchs, Ilaria Carena, Pascal Furet, Carlos Garc|¤a Echeverr|¤a
Novartis K125 442, Oncology Department, CH-4002 Basel, Switzerland
Received 30 April 2002; revised 6 August 2002; accepted 19 August 2002
First published online 11 September 2002
Edited by Richard Marais
Abstract Inhibitors of the p53^hdm2 interaction are attractive
molecules for stimulating the p53 pathway in tumors. In this
report, an inhibitor of the p53^hdm2 interaction, the AP pep-
tide, is used to activate p53 in tumor cells expressing various
levels of hdm2 protein. It induces apoptosis only in cells express-
ing high endogenous levels of hdm2 protein. The absence of
apoptosis in tumor cells with low hdm2 levels is due not to
alterations in the p53-dependent apoptotic pathway but to a
di¡erent regulation of this pathway. The peptide is also less
toxic for non-tumor cells than for tumor cells overexpressing
the hdm2 protein.
# 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The hdm2 protein regulates the activity of the p53 protein
in at least three di¡erent ways [1]. First, it binds to the p53
transactivation domain, inhibiting its transcriptional activity
[2]. Second, upon binding to p53, it induces p53 nuclear ex-
port [3]. Third, it stimulates p53 degradation [4,5]. Several
cellular pathways target the p53^hdm2 interaction. For exam-
ple, oncogenic proteins such as ras or myc induce the expres-
sion of the p14ARF protein, which upon binding to hdm2
prevents p53 degradation [6,7]. Similarly, genotoxic stresses
induce the phosphorylation of p53 within the hdm2-binding
site, preventing an interaction between the two proteins [8].
The disruption of the p53^hdm2 interaction is therefore a
mechanism used by the cell to modulate the p53 pathway.
Since hdm2 is ampli¢ed in various tumors [9], inhibitors of
the p53^hdm2 interaction could be used as anticancer agents
to treat these cancers, therefore having potential applications
in medicine. Recently, we showed that a small synthetic pep-
tide that inhibits the p53^hdm2 interaction in vitro stimulates
the p53 pathway in tumor cells [10]. When applied directly to
the cell culture medium, this 8-mer untagged peptide [11], the
AP peptide, activates the p53 pathway only in the presence of
wild-type p53 protein.
In this report, we analyze the biological consequences of AP
peptide treatments in cells that express di¡erent levels of
hdm2 protein.
2. Materials and methods
2.1. Cell lines
The HCT 116, JAR and SJSA-1 cells express wild-type p53. The
H1299 cells express the p14ARF protein and lack the p53 protein [12],
the SK-BR-3 cells express a mutated p53 protein [13] and the Saos-2
cells express a truncated pRb protein [14]. The NHDF 710 (normal
human dermal ¢broblasts) and the HMEC 2595 (human mammary
epithelial cells) are non-tumor cells.
2.2. Preparation of the peptides
The sequences of the peptides are:
AP peptide: Ac-Phe-Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3c-Leu-NH2
IP peptide: Ac-Phe-Met-Aib-Pmp-Ala-Glu-Ac3c-Leu-NH2,
where Aib is K-aminoisobutyric acid, Pmp is phosphonomethylphe-
nylalanine, 6-Cl-Trp is 6-chloro-tryptophan and Ac3c is 1-aminocy-
clopropanecarboxylic acid. The synthesis, the analytical and biological
characterization of the AP and IP peptides have been previously re-
ported [10,11]. Unless otherwise indicated, the AP and IP peptides
were used at the concentration of 500 WM in the cellular assays.
2.3. Western blot and ELISA
The hdm2, pRb, p14ARF, p21Waf1=Cip1, procaspase-9 and L-tubulin
proteins were detected by Western blot using the IF2, clone LM95.1,
p14ARF Ab-1, EA10, polyclonal rabbit anti-caspase-9 and TUB 2.1
antibodies, respectively. The cellular amounts of the p53 protein were
determined by ELISA as previously described [10].
2.4. Cell proliferation assay, measurement of caspase-3 activity and
FACS analysis
The cell proliferation assay and the measure of caspase-3 activity
have been conducted as previously described [10]. The FACS analyses
were performed as follows. The cells, treated during 72 h with 500 WM
AP peptide, were harvested and stained with propidium iodide. The
FACS analysis was realized with an Excalibur £ow cytometer (Becton
Dickinson) equipped with CellQuest software.
2.5. Measurement of cytochrome-c release
After 24 h seeding the cells were incubated in the presence of AP or
IP peptide for 48 h. The release of cytochrome-c from the mitochon-
dria was measured using an ApopAlert Cell Fractionation kit (Clone-
tech) according to the instructions provided by the manufacturers.
3. Results
3.1. Determination of p53, hdm2, p14ARF and pRB endogenous
levels
Low levels of p53 protein are found in the HCT 116 and
JAR cells (Fig. 1A). These levels are higher than the back-
ground values obtained in the p53-negative cells, H1299, but
lower than in the p53-mutant expressing cell line SK-BR-3. In
SJSA-1 cells, the p53 levels are low and comparable to the
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background value measured in the H1299 cells. The hdm2
protein is detected in the three cell lines but is overexpressed
in the JAR and SJSA-1 cells, as previously described [15]
(Fig. 1B). In agreement with a previous report [12], the three
wild-type p53 expressing cell lines contain lower amounts of
p14ARF protein than the p53-negative cells, H1299 (Fig. 1C).
The pRb protein is detected in the three cell lines but not in
the pRb-negative cell line Saos-2 (Fig. 1D).
3.2. Induction of p53 and p21Waf1=Cip1 proteins by AP peptide
The AP peptide, but not its inactive analog the IP peptide,
induces a weak but reproducible accumulation of p53 in the
three cell lines (Fig. 2A). Since the AP peptide induces p53
accumulation, the question was raised as to whether it also
stimulates its transcriptional activity. Induction of the
p21Waf1=Cip1 protein, which is transcriptionally regulated by
p53 [16], was measured (Fig. 2B). The AP peptide, but not
the IP peptide, induces the accumulation of the p21Waf1=Cip1
protein in all the cell lines. The AP peptide did not induce the
accumulation of the p21Waf1=Cip1 protein in the p53-negative
cell line Saos-2. Similar results were obtained with the hdm2
protein (data not shown), another gene transcriptionally regu-
lated by p53 [17], in agreement with previous data [10].
3.3. E¡ect of AP peptide on cell proliferation and viability
The AP peptide, but not the IP peptide, inhibits the prolif-
eration of the HCT 116, JAR and SJSA-1 cells (Fig. 3A). The
AP peptide-mediated inhibition of tumor cell proliferation can
be the consequence of an induction either of cell cycle arrest
or of apoptosis. The activation of caspase-3 during p53-medi-
ated apoptosis [18] o¡ers the possibility of determining
whether the AP peptide induces p53-mediated apoptosis.
The experimental results show that caspase-3 is activated in
JAR and SJSA-1 cells but not in HCT 116 cells (Fig. 3B).
This, together with the proliferation experiments (Fig. 3A),
suggests that the AP peptide induces a cell cycle arrest in
the HCT 116 cells and apoptosis in the JAR and SJSA-1 cells.
To con¢rm these data, the e¡ect of the AP peptide on the cell
cycle of the three cell lines was analyzed by FACS (Fig. 3C).
The results show that the AP peptide induces an increase in
the G0/G1 and G2/M populations in HCT 116 cells, suggest-
ing a cell cycle arrest. In contrast, there is an increase in the
sub-G1 population in both the JAR and SJSA-1 cells reveal-
ing the induction of apoptosis.
Fig. 1. Endogenous levels of the p53, hdm2 p14ARF and pRb pro-
teins. The endogenous levels of the p53 (A), hdm2 (B), p14ARF (C)
and pRB (D) were determined by ELISA (A) or Western blot. The
H1299 cells were used as p53-negative and p14ARF-positive control
cells, the Saos-2 cells as pRb-negative cells and the SK-BR-3 cells
as p53 overexpressing cells. The tubulin content of the di¡erent ex-
tracts was also detected by Western blot. The molecular weights are
indicated.
Fig. 2. Induction of the p53 and p21Waf1=Cip1 proteins by AP pep-
tide. A: After 24 h treatment with AP peptide (black bars) or IP
peptide (white bars), the accumulation of the p53 protein was deter-
mined by quantitative ELISA. The induction of p53 was normalized
to the amount of the p53 protein present in the corresponding un-
treated cells (arbitrarily taken as 1). Fold induction p53 corresponds
to the ratio between the amount of p53 present in the treated cells
and that in the untreated cells. The amount of p53 detected in the
p53-negative cells, Saos-2, corresponds to the background value of
the assay. B: The p21Waf1=Cip1 protein present in the untreated cells
or in the cells treated for 24 h with 500 WM AP or IP peptide was
detected by Western blot. The tubulin content of the di¡erent ex-
tracts was also detected by Western blot. The molecular weights are
indicated.
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3.4. Analysis of the p53-dependent apoptotic pathway in
HCT 116 cells
The absence of caspase-3 activity in the HCT 116 cells after
AP peptide treatment could be explained by the fact that
when the p21Waf1=Cip1 protein binds to procaspase-3 [19] it
prevents caspase-3 activation. Alternatively, the conversion
of procaspase-3 into its active form by caspase-9, a mediator
of p53-dependent apoptosis [20], could be prevented. We
therefore determined whether procaspase-9 is processed after
AP peptide treatment (Fig. 4A). The procaspase-9 protein
present in HCT 116 cells is not processed upon AP peptide
treatment, while it is processed in SJSA-1 cells in which cas-
pase-3 is activated (Fig. 3B). Therefore, no caspase-3 activity
is detected in the HCT 116 cells because its activating enzyme,
caspase-9, is not activated. During apoptosis, cytochrome-c is
released from the mitochondria into the cytoplasm, where it
initiates dATP-dependent oligomerization of Apaf-1. Procas-
pase-9 is then recruited and converted into its active form,
caspase-9 [21]. Since p53 induces the release of cytochrome-c
from the mitochondria [22], we investigated whether the AP
peptide stimulates this release. Our results show that the cy-
tochrome-c protein remains in the mitochondrial fractions of
untreated cells or HCT 116 cells treated with AP and IP pep-
tide (Fig. 4B). Therefore, the AP peptide-mediated activation
of the p53 protein does not lead to the release of cytochrome-c
from the mitochondria in HCT 116 cells.
Fig. 3. E¡ect of AP peptide on cell proliferation and viability.
A: The cells were treated for 72 h with AP peptide (black bars) or
IP peptide (white bars), and the number of viable cells measured.
The data were normalized to the number of cells present in the cor-
responding untreated samples. B: The cells were treated for 72 h
with the AP peptide (black bars) or IP peptide (white bars), and the
caspase-3 activity present in the cellular lysates was determined.
Fold induction caspase-3 activity corresponds to the ratio between
the caspase-3 activity present in the treated cells and that detected
in the untreated cells (arbitrarily taken as 1). C: The cells were
treated for 72 h with the AP peptide stained with propidium iodide,
and their DNA content analyzed by FACS. The ¢gure represents
the percent of change in cell cycle distribution after AP peptide
treatment.
Fig. 4. Analysis of the p53-dependent apoptotic pathway in HCT
116 cells. A: The HCT 116 and the SJSA-1 cells were incubated for
48 h in the absence (untreated) or presence of AP or IP peptide.
The content of procaspase-9 and tubulin in the di¡erent cells was
measured by Western blot. B: The HCT 116 cells were incubated
for 48 h in the absence (untreated) or presence of AP or IP peptide.
Cytosolic (C) and mitochondrial (M) extracts were prepared and the
cytochrome-c was detected by Western blot.
Fig. 5. The AP peptide is more toxic to tumor cells than to non-tu-
mor cells. A: The tumor cells SJSA-1 (open circles) and non-tumor
cells NHDF 710 (open triangles) and HMEC 2595 (open squares)
were treated for 72 h with di¡erent concentrations of AP peptide
and the number of viable cells was measured. B: The p21Waf1=Cip1
protein present in the extracts of untreated cells (3AP) or cells
treated for 24 h with AP peptide (+AP) was detected by Western
blot. The tubulin content of the di¡erent extracts was also deter-
mined.
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3.5. The AP peptide is more toxic for tumor than for
non-tumor cells
The AP peptide-mediated induction of apoptosis in the
JAR and SJSA-1 cells suggests that inhibitors of the p53^
hdm2 interaction could be useful drugs to treat tumors ex-
pressing high hdm2 levels. However, the hdm2 protein is a
natural regulator of the p53 protein, and the inhibition of the
p53^hdm2 interaction stimulates p53 activity in non-tumor
cells [23]. Therefore, such molecules may be toxic inducing
cell death also in non-tumor tissues. To address this issue
the non-tumor cells NHDF 710 and HMEC 2595 were treated
with the AP peptide and their viability measured. For com-
parison, the AP peptide-sensitive tumor cells, SJSA-1, were
included in the experiments. The experimental data show
that the AP peptide inhibits the proliferation of tumor cells
more e¡ectively than non-tumor cells (Fig. 5A). To verify that
the lack of e¡ect of the AP peptide in NHDF 710 and HMEC
2595 cells is not due to a poor penetration of this compound
in these cells, the induction of the p21Waf1=Cip1 protein was
measured (Fig. 5B). The AP peptide induces the accumulation
of the p21Waf1=Cip1 protein in the three cell lines, demonstrat-
ing that it penetrates them in a similar fashion.
4. Discussion
In this report, we study the e¡ect of the activation of the
p53 pathway by a synthetic inhibitor of the p53^hdm2 inter-
action, the AP peptide, in three cell lines expressing di¡erent
levels of hdm2 protein. The HCT 116, JAR and SJSA-1 cells
express low, intermediate and high hdm2 levels, respectively.
These cell lines were chosen because we did not ¢nd exactly
matched tumor cell lines expressing very di¡erent levels of
hdm2 protein. The HCT 116, JAR and SJSA-1 cells contain
similar levels of the p14ARF and pRb proteins, two key medi-
ators of the p53 pathway, and they all express the wild-type
p53 protein.
The AP peptide induces a low accumulation of the p53
protein in these cells. This weak e¡ect may be explained by
the poor bioavailability of the inhibitor due to its peptidic
character and its high polarity. Another possibility is that the
accumulated p53 stimulates the expression of the hdm2 pro-
tein, which in turn induces its degradation. However, despite
this slight accumulation, the accumulated p53 protein induces
a large expression of the p21Waf1=Cip1 protein. Since the AP
peptide has no e¡ect on p21Waf1=Cip1 levels in both p53-
negative and p53-mutant expressing cells [10], the accumula-
tion observed in the three cell lines studied is not due to a
p53-independent mechanism. These data show that even a
weak accumulation of the p53 protein can lead to a signi¢-
cant induction of p53-dependent genes such as p21Waf1=Cip1.
The AP peptide-mediated stimulation of the p53 pathway
a¡ects di¡erently the proliferation of the three cell lines. It
induces apoptosis in the JAR and SJSA-1 but not in the
HCT 116 cells. Very interestingly, the induction of apoptosis
correlates with the cellular content of hdm2 protein. The
more the cell expresses hdm2 the more it is susceptible to
AP peptide-mediated apoptosis. This observation should be
further validated with the study of other hdm2 overexpress-
ing cell lines. Previous work has shown that the fate of the
HCT 116 cells after p53 activation depends on the presence
of the p21Waf1=Cip1 protein. In its presence, they undergo a
cell cycle arrest ; in its absence, however, they die from apo-
ptosis [18]. This indicates that the p53-dependent apoptotic
pathway is functional in the HCT 116 cells and that the
absence of AP peptide-mediated apoptosis in these cells can-
not be explained by an alteration of this pathway. We show
that the AP peptide-mediated activation of p53 in the HCT
116 cells does not induce the release of the cytochrome-c
protein from the mitochondria and, consequently, does not
initiate the processing of procaspase-9 and procaspase-3.
This suggests that in the presence of the p21Waf1=Cip1 protein
the biochemical events leading to the release of cytochrome-c
from the mitochondria are prevented during p53-mediated
apoptosis. The e¡ect of the AP peptide on two other tumor
cell lines, U-2 OS and MCF7, expressing low hdm2 levels was
also investigated. The peptide activates p53 in these cells with-
out inducing apoptosis (data not shown). In the course of this
work we also tried to obtain stable HCT 116 clones expressing
high levels of hdm2 protein but our attempts were unsuccess-
ful, suggesting that high hdm2 levels are not tolerated in these
cells.
Our ¢ndings indicate that the AP peptide induces preferen-
tially apoptosis in cells overexpressing the hdm2 protein.
Therefore, the peptide should a¡ect to a lower extent the
viability of non-tumor cells which express very low levels of
hdm2 protein, than that of hdm2-overexpressing tumor cells.
Indeed, we show that the AP peptide-mediated activation of
p53 a¡ects less the proliferation of non-tumor cells than it
does with hdm2 overexpressing tumor cells. In agreement
with previous data [23], we show that the inhibition of the
p53^hdm2 interaction induces p53 activation in normal ¢bro-
blasts. However, our results reveal that inhibitors of the p53^
hdm2 interaction are more toxic for hdm2 overexpressing tu-
mor cells than for non-tumor cells. Therefore, if this thera-
peutic window is retained in vivo, inhibitors of the p53^hdm2
interaction will be particularly useful for treating tumors with
ampli¢ed hdm2. The analysis of hdm2 ampli¢cation in about
4000 tumor and xenograft samples shows that hdm2 is ampli-
¢ed in 7% of them [9].
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